Differential Effects of High Methionine Diet on Biochemical Parameters in Normal and Diabetic Rat Models

Yongwei Jiang, Meimei Zhao, Mo Li, Haoyan Zhu, Xiaomu Kong, Qian Liu, Yi Liu, Peng Gao, Guo‐Xiong Deng, Hailing Zhao, Ming Yang, Yongtong Cao, Ping Li, Liang MaExperimental 2025 · DOI

Abstract

This study investigated the organ-specific effects of a high-methionine (HM) diet in streptozotocin (STZ)-induced diabetic rats, focusing on hepatic and renal metabolic adaptations. Male Wistar rats were divided into four groups (n=8/group): normal control, HM (2% methionine), STZ-diabetic, and HM+STZ. Over 12 weeks, HM supplementation in diabetic rats significantly reduced hepatic triglyceride accumulation (42.00±7.71 vs. 20.76±3.63 mg/g tissue, P<0.01), coinciding with AMP-activated protein kinase (AMPK) activation (1.96-fold, P<0.05) and downregulation of lipogenic genes (sterol regulatory element-binding protein 1c ↓63.2%, P<0.05). Conversely, HM exacerbated diabetic nephropathy, elevating urinary albumin-creatinine ratio (411.90±88.86 vs. 238.41±62.52 mg/g, P<0.05) and glomerulosclerosis index (2.5±0.5 vs. 1.8±0.4, P<0.001). Hyperhomocysteinemia (105.69±33.81 μmoI/L) persisted across HM groups without altering folate/vitamin B12 levels (P>0.05). These findings demonstrate a striking dichotomy: HM diet ameliorates hepatic steatosis through AMPK-mediated lipid modulation while accelerating renal injury via homocysteine-dependent pathways. The results highlight the need for organ-specific nutritional strategies in diabetes management.

Introduction

Patients with diabetes mellitus frequently face a constellation of complications, including non-alcoholic fatty liver disease (NAFLD) and diabetic nephropathy. Methionine, an essential sulfur-containing amino acid, plays a pivotal role in methylation and antioxidant production. However, its metabolic byproduct, homocysteine, is toxic at high concentrations. While methionine restriction has been proposed as a metabolic intervention, the effects of a high-methionine (HM) diet in the context of active diabetes remain controversial. This study aimed to determine whether methionine supplementation exerts uniform effects across different organs or triggers divergent metabolic adaptations in the liver versus the kidney.

Methods

The researchers conducted a 12-week longitudinal study using male Wistar rats divided into four cohorts: Normal Control, HM Group (2% methionine), STZ Group (streptozotocin-induced diabetes), and HM+STZ Group. Biochemical profiling was performed to track plasma homocysteine, glucose, and liver enzymes (ALT/AST). Molecular analyses, including qPCR and Western Blotting, were utilized to monitor the expression of lipogenic genes (SREBP-1c, ACC) and the activation of the metabolic master-switch, AMPK. Histopathological assessments quantified kidney damage via the Glomerulosclerosis Index (GSI).

Results

Systemic Biochemical Profiles and Hepatic Steatosis

The administration of an HM diet to diabetic rats resulted in a significant modulation of hepatic lipid metabolism. As shown in Figure 3, while STZ treatment alone induced marked elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the addition of 2% methionine (HM+STZ group) significantly attenuated these markers of liver injury. Most notably, hepatic triglyceride content was reduced by approximately 50% in the HM+STZ group compared to the STZ group (20.76±3.63 vs. 42.00±7.71 mg/g tissue, P<0.01).

Biochemical parameters and hepatic triglyceride content across experimental groups over 12 weeks.

Molecular Mechanisms of Hepatic Protection

The underlying mechanism for this hepatic rescue involves the activation of the AMP-activated protein kinase (AMPK) pathway. Western blot analysis revealed a 1.96-fold increase in the p-AMPK/AMPK ratio in the HM+STZ group (Figure 6). This activation was accompanied by a significant increase in hepatic glutathione (GSH) levels and a reduction in malondialdehyde (MDA), suggesting enhanced antioxidant capacity. Furthermore, lipogenic genes SREBP-1c and ACC were downregulated by 63.2% and 46.05%, respectively, in the HM+STZ group compared to the STZ-only group.

Hepatic oxidative stress markers and AMPK activation in response to high methionine diet.

Renal Vulnerability and Hyperhomocysteinemia

In contrast to the hepatic benefits, the HM diet exacerbated renal dysfunction. Diabetic rats receiving methionine supplementation exhibited a 72.8% increase in the urinary albumin-creatinine ratio (UACR) and a significantly higher Glomerulosclerosis Index (GSI). This renal decline is attributed to severe hyperhomocysteinemia (HHcy) induced by the HM diet, with plasma homocysteine levels reaching ~100 μmoI/L—roughly ten times higher than control levels—throughout the 12-week period.

Discussion and Conclusion

This study reveals a metabolic "double-edged sword": a high-methionine diet ameliorates hepatic steatosis by activating AMPK signaling and reducing lipid accumulation, yet simultaneously accelerates diabetic nephropathy via elevated homocysteine levels. The liver's robust transsulfuration capacity allows it to utilize methionine for antioxidant production and lipid clearance, whereas the kidney's relative lack of this capacity leaves it vulnerable to homocysteine-induced fibrosis and podocyte injury.

These findings underscore the critical need for organ-specific nutritional strategies in diabetes management. While methionine supplementation might offer therapeutic potential for fatty liver, its detrimental effects on renal health suggest that a "one-size-fits-all" approach to amino acid supplementation is inappropriate for patients with multi-organ diabetic complications. Future research should utilize tissue-specific knockout models to further delineate these divergent signaling pathways and explore the long-term sustainability of the hepatic benefits.

Summary updated

Abstract

This study investigated the organ-specific effects of a high-methionine (HM) diet in streptozotocin (STZ)-induced diabetic rats, focusing on hepatic and renal metabolic adaptations. Male Wistar rats were divided into four groups (n=8/group): normal control, HM (2% methionine), STZ-diabetic, and HM+STZ. Over 12 weeks, HM supplementation in diabetic rats significantly reduced hepatic triglyceride accumulation (42.00±7.71 vs. 20.76±3.63 mg/g tissue, P<0.01), coinciding with AMP-activated protein kinase (AMPK) activation (1.96-fold, P<0.05) and downregulation of lipogenic genes (sterol regulatory element-binding protein 1c ↓63.2%, P<0.05). Conversely, HM exacerbated diabetic nephropathy, elevating urinary albumin-creatinine ratio (411.90±88.86 vs. 238.41±62.52 mg/g, P<0.05) and glomerulosclerosis index (2.5±0.5 vs. 1.8±0.4, P<0.001). Hyperhomocysteinemia (105.69±33.81 μmol/L) persisted across HM groups without altering folate/vitamin B12 levels (P>0.05). These findings demonstrate a striking dichotomy: HM diet ameliorates hepatic steatosis through AMPK-mediated lipid modulation while accelerating renal injury via homocysteine-dependent pathways. The results highlight the need for organ-specific nutritional strategies in diabetes management.
BibTeX
@inproceedings{jiang2025differential,
  author = {Yongwei Jiang and Meimei Zhao and Mo Li and Haoyan Zhu and Xiaomu Kong and Qian Liu and Yi Liu and Peng Gao and Guo‐Xiong Deng and Hailing Zhao and Ming Yang and Yongtong Cao and Ping Li and Liang Ma},
  title = {{Differential Effects of High Methionine Diet on Biochemical Parameters in Normal and Diabetic Rat Models}},
  booktitle = {Experimental},
  year = {2025},
  doi = {10.1055/a-2686-7562},
}
Figure